Key facts
- This page summarizes Kynam Global Healthcare Master Fund, LP's Form 4 filing for 2seventy bio, Inc. (TSVT).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 13 Mar 2025, 18:18.
Kynam Global Healthcare Master Fund, LP - 11 Mar 2025 Form 4 Insider Report for 2seventy bio, Inc. (TSVT)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TSVT
- Reported as of
- 11 Mar 2025
- Net transaction value
- -$80,053,572
- SEC form
- 4
- Accepted by SEC
- 13 Mar 2025, 18:18:22 UTC
- Prior SEC filing
- 16 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- KYNAM GLOBAL HEALTHCARE MASTER FUND, LP, By: KYNAM FUND GP, LLC, By: /s/ Yue Tang, Yue Tang, Managing Member
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kynam Global Healthcare Master Fund, LP filed Form 4 for 2seventy bio, Inc. (TSVT) on 13 Mar 2025.
Change
- Previous filing in this sequence was filed on 16 Aug 2023.
- Current net transaction value: -$80,053,572.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TSVT
transaction
Common Stock, par value $0.0001 per share
Sale
- Transaction value
- $29,352,357
- Shares
- -5,953,825
- Change %
- -100%
- Price
- $4.93
- Shares after
- 0
- Date
- 11 Mar 2025
- Ownership
- See Footnote
- Footnotes
- F1
TSVT
transaction
Common Stock, par value $0.0001 per share
Sale
- Transaction value
- $25,350,607
- Shares
- -5,142,111
- Change %
- -100%
- Price
- $4.93
- Shares after
- 0
- Date
- 11 Mar 2025
- Ownership
- Direct
- Footnotes
- F2
TSVT
transaction
Common Stock, par value $0.0001 per share
Sale
- Transaction value
- $25,350,607
- Shares
- -5,142,111
- Change %
- -100%
- Price
- $4.93
- Shares after
- 0
- Date
- 11 Mar 2025
- Ownership
- See Footnote
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Kynam Global Healthcare Master Fund, LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
The reported securities are owned directly by Kynam Global Healthcare Master Fund, LP (the "Master Fund"), a private investment fund managed by Kynam Capital Management, LP (the "Adviser"), and separately managed account clients of the Adviser and may be deemed to be indirectly beneficially owned by (i) the Adviser, (ii) Kynam Capital Management GP, LLC (the "Adviser GP"), the general partner of the Adviser and (iii) Yue Tang, the managing member of the Adviser GP. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F2
The reported securities are directly owned by the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F3
The reported securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by Kynam Fund GP, LLC, the general partner of the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.